RSSCategory: Health Policy

Taken for a ride? Ambulances stick patients with surprise bills

Taken for a ride? Ambulances stick patients with surprise bills

One patient got a $3,600 bill for a 4-mile ride. Another was charged $8,460 for a trip from one California hospital that could not handle his case to a facility that could. Still another found herself marooned at an out-of-network hospital, where she’d been taken by ambulance without her consent.

November 21, 2017 | By | Reply More
How older patients can dodge pitfalls entrenched in our health system

How older patients can dodge pitfalls entrenched in our health system

The US health care system serves the elderly poorly. A new book provides guidance to help seniors receive the best care possible.

November 16, 2017 | By | Reply More
How other countries achieve universal coverage

How other countries achieve universal coverage

While the term single-payer is often used to describe the way a number of other nations with universal coverage organize their health systems, it glosses over significant differences across those systems.

November 7, 2017 | By | Reply More
House tax bill would scrap deduction for medical expenses

House tax bill would scrap deduction for medical expenses

The tax bill unveiled by Republicans in the House on Thursday would not, as had been rumored, eliminate the tax penalty for failure to have health insurance. But it would eliminate a decades-old deduction for people with very high medical costs.

November 3, 2017 | By | Reply More
New gene therapies could cost more than $1m per patient

New gene therapies could cost more than $1m per patient

Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country’s first gene therapy, Novartis’ Kymriah, a leukemia treatment approved in August. But the total costs of Kymriah and the 21 similar drugs in development — known as CAR T-cell therapies — will be far higher than many have imagined, reaching $1 million or more per patient.

October 17, 2017 | By | Reply More
Trump’s order advances GOP go-to ideas to broaden insurance choice, curb costs

Trump’s order advances GOP go-to ideas to broaden insurance choice, curb costs

Trump’s order would signals a shift in the administration’s strategy, which relied on Congress to repeal the Affordable Care Act. Trump is now using the force of his executive rule-making authority to implement long-favored GOP policy alternatives.

October 12, 2017 | By | Reply More
Training new doctors right where they’re needed

Training new doctors right where they’re needed

Dr. Olga Meave didn’t mind the dry, 105-degree heat that scorched this Central Valley city on a recent afternoon. The sweltering summer days remind her of home in Sonora, Mexico. So do the people of the Valley — especially the Latino first-generation immigrants present here in large numbers, toiling in the fields or piloting big rigs laden with fruits and vegetables.

October 9, 2017 | By | Reply More
States scramble to overcome Congress’ failure to move on CHIP

States scramble to overcome Congress’ failure to move on CHIP

Congress’ failure to reauthorize the Children’s Health Insurance Program leaves states facing difficult choices about who will continue to get health coverage.

October 6, 2017 | By | Reply More
Flat-fee primary care helps fill niche for Texas’ uninsured

Flat-fee primary care helps fill niche for Texas’ uninsured

Under the practice model, called direct primary care, patients are charged monthly — typically $20 to $75, depending on age, in Graham’s practice — for basic, office-based medical care and frequently cell phone and other after-hours physician access.

October 3, 2017 | By | Reply More
Do pharma’s claims on drug prices pass the mell test? We found 5 stinkers.

Do pharma’s claims on drug prices pass the mell test? We found 5 stinkers.

Inventing, testing and launching a drug costs $2.6 billion, calculates the Tufts Center for the Study of Drug Development. But industry substantially finances the center’s work. An independent study found the median cost of developing 10 cancer drugs was $648 million, while the median revenue per drug was $1.7 billion.

October 2, 2017 | By | Reply More